May 31, 20231 min readExplore Lunsumio ~ June 6th, 2023Check out this upcoming event! RSVP and grab a seat today!Lunsumio 6.6.23.pdfDownload PDF • 184KB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
Combined Power to Change the Game: RYBREVANT® + LAZCLUZE™ in First-Line Treatment of EGFR+* Locally Advanced or mNSCLC ~ Thursday, 10/24/24
Comments